文献速递血栓与止血

肝硬化住院患者肝素的体外抗凝效果充分

Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis.
PubMed 文献 · J Thromb Haemost · 2021-04-09

本研究在真实临床环境中评估肝硬化患者预防性低分子肝素或普通肝素剂量的抗凝效果。结果显示,肝硬化及慢加急性肝衰竭患者与无肝病患者的凝血酶生成变化相似,提示当前预防剂量肝素抗凝效果相当。

要点

  • 肝硬化患者预防剂量肝素的抗凝效果与无肝病患者相当。
  • 抗Xa活性与低分子肝素引起的凝血酶生成变化相关,但与普通肝素无关。
  • 慢加急性肝衰竭患者凝血酶-抗凝血酶复合物水平未下降,需关注。

核心结论

  • 当前预防性肝素剂量在肝硬化患者中具有与无肝病患者相当的抗凝效果。

研究设计与样本

  • 研究纳入肝硬化患者16例、慢加急性肝衰竭患者14例,分别与无肝病普通内科病房患者18例、无肝病重症监护室患者14例比较。
  • 在首次低分子肝素或普通肝素给药前及给药后4小时采血,使用凝血酶生成试验、凝血酶-抗凝血酶复合物及常规凝血试验评估止血状态。
  • 纳入健康对照20例以建立参考值,并测定抗Xa活性以估计肝素峰值水平。

主要发现

  • 尽管常规凝血试验有改变,所有队列及健康对照的基线凝血酶生成相似。
  • 肝素作用下,四个队列的凝血酶生成绝对和比例变化相当(-62%至-85%)。
  • 除慢加急性肝衰竭队列外,所有队列的凝血酶-抗凝血酶复合物水平均下降,但与凝血酶生成比例变化不相关。
  • 抗Xa活性与低分子肝素治疗患者的凝血酶生成比例变化相关,但与普通肝素治疗患者不相关。

临床怎么用

  • 肝硬化住院患者可按当前预防剂量使用肝素进行血栓预防,抗凝效果与无肝病患者相当。
  • 慢加急性肝衰竭患者使用肝素时凝血酶-抗凝血酶复合物未下降,需进一步评估抗凝反应。

局限性

  • 样本量较小,肝硬化16例、慢加急性肝衰竭14例、无肝病普通内科18例、无肝病重症监护室14例。
  • 仅评估首次给药后4小时的体外抗凝效果,未报告临床血栓或出血结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with cirrhosis are at risk of venous thromboembolism (VTE), but strategies for thromboprophylaxis have not been defined. Previous in vitro studies suggest an altered anticoagulant effect of heparins in patients with cirrhosis. OBJECTIVES: To assess the anticoagulant effects of prophylactic low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) doses in patients with cirrhosis in a real-life clinical setting. METHODS: We studied patients with cirrhosis (n = 16) and acute-on-chronic liver failure (ACLF) (n = 14), and compared these with patients without underlying liver disease admitted to non-liver general medical wards (n = 18) and non-liver intensive care units (n = 14), respectively. Blood samples were taken before and 4 h after administration of the first dose of LMWH or UFH. We assessed hemostatic status using thrombin generation assays, thrombin-antithrombin complexes (TAT), and conventional coagulation assays, and included healthy controls (n = 20) to establish reference values. Anti-Xa activity was determined to estimate peak heparin levels. RESULTS: Baseline thrombin generation was similar among all cohorts and healthy controls despite alterations in conventional coagulation assays. On heparin, both absolute and proportional changes of thrombin generation were comparable between all four cohorts (-62% to -85%). TAT levels decreased in all cohorts apart from the ACLF cohort, but did not correlate with the proportional change in thrombin generation. Anti-Xa activity correlated with the proportional change in thrombin generation in patients receiving LMWH, but not in patients receiving UFH. CONCLUSIONS: These data suggest that current prophylactic heparin doses have comparable anticoagulant effects in patients with cirrhosis compared with patients without underlying liver disease.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. van den Boom BP, von Meijenfeldt FA, Adelmeijer J, et al. Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis. J Thromb Haemost. 2021. PMID: 33725411. doi:10.1111/jth.15296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。